Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART)
- 94 Downloads
Cerebrospinal fluid (CSF)/plasma HIV-RNA ratio has been associated with residual neurocognitive impairment on cART, leading us to hypothesize a specific peripheral and/or CSF immune feature in patients with high CSF/plasma ratio (≥ 1). In patients with diverse pre-cART CSF/plasma ratio (61/70 with CSF/plasma ratio < 1, L-CSF, 9/70 with CSF/plasma ratio ≥ 1, H-CSF), we investigated the effects of 12 months of effective cART on peripheral and CSF inflammatory markers, on T cell activation/maturation and HIV/CMV-specific intracellular cytokine pattern. We also studied the possible clinical association between peripheral/CSF pro-inflammatory milieu and neurocognitive screening tests (MMSE, FAB, IHDS). Prior to cART, the two groups were comparable for peripheral and CSF inflammation, T cell activation/proliferation and maturation, and HIV/CMV-specific response. Upon cART initiation, both H-CSF and L-CSF featured a significant reduction in plasma TNF-α and circulating CD8 activation, with a redistribution of memory/naïve T cell subsets in L-CSF alone. In the CSF compartment, cART seemed able to reduce pro-inflammatory cytokine/chemokine levels in both H-CSF and L-CSF patients. Interestingly, despite a reduction in the pro-inflammatory milieu, no changes were shown in neurocognitive screening tests in both patients’ groups. We hereby show that 12-month cART is able to reduce intratechal and peripheral pro-inflammatory burden; a longer cART exposure and a more comprehensive neuropsychological evaluation might be necessary to gain a broader insight into the possible effects on neurocognitive performance.
KeywordsCSF/plasma HIV-RNA ratio HIV-associated neurocognitive disorders Peripheral immune activation CSF inflammatory markers
We thank all of the patients who participated in the study and the staff of the Clinic of Infectious Diseases and Tropical Medicine at “ASST Santi Paolo e Carlo”, Milan and of Amedeo di Savoia Hospital, Turin who cared for the patients. Presented in part at 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, B.C., Canada (19-22 July2015). Oral Poster #TUPDA0101.
This study was supported by Gilead Fellowship 2012 grant number F61bd8c044 to G.M.
Compliance with ethical standards
Ethics approval and consent to participate
The ethics committee of the Clinic of Infectious Diseases, University of Milan-ASST Santi Paolo e Carlo, Milan and of Amedeo di Savoia Hospital, Turin (Italy) approved this study. All subjects gave written informed consent in accordance with the Declaration of Helsinki.
Conflict of interest
E.M., F.I., A.C., F.B., M.T., A.D.M., and S.B. declare that they have no conflict of interests. G.M. received research grant by Gilead.
- Calcagno A, Romito A, Atzori C, Ghisetti V, Cardellino C, Audagnotto S, Scarvaglieri E, Lipani F, Imperiale D, Di Perri G, Bonora S (2017) Blood brain barrier impairment in HIV-positive naive and effectively treated patients: immune activation versus Astrocytosis. J NeuroImmune Pharmacol 12:187–193CrossRefPubMedGoogle Scholar
- Dentone C, Fenoglio D, Schenone E, Cenderello G, Prinapori R, Signori A, Parodi A, Kalli F, Battaglia F, Feasi M, Bruzzone B, Viscoli C, Filaci G, Di Biagio A (2015) Increased CD38 expression on T lymphocytes as a marker of HIV dissemination into the central nervous system. HIV Clin Trials 16:190–196CrossRefPubMedGoogle Scholar
- Eden A, Marcotte TD, Heaton RK, Nilsson S, Zetterberg H, Fuchs D, Franklin D, Price RW, Grant I, Letendre SL, Gisslen M (2016) Increased intrathecal immune activation in virally suppressed HIV-1 infected patients with neurocognitive impairment. PLoS One 11:e0157160CrossRefPubMedPubMedCentralGoogle Scholar
- Ellis RJ, Moore DJ, Childers ME, Letendre S, McCutchan JA, Wolfson T, Spector SA, Hsia K, Heaton RK, Grant I (2002) Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol 59:923–928CrossRefPubMedGoogle Scholar
- Gouse H, Casson-Crook M, Decloedt EH, Joska JA, Thomas KGF (2017) Adding a brief self-report cognitive tool to the IHDS improves effectiveness of identifying patients with HIV-associated dementia in South Africa. J Neuro-Oncol 23:686–695Google Scholar
- Grauer OM, Reichelt D, Gruneberg U, Lohmann H, Schneider-Hohendorf T, Schulte-Mecklenbeck A, Gross CC, Meuth SG, Wiendl H, Husstedt IW (2015) Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid. Ann Clin Transl Neurol 2:906–919CrossRefPubMedPubMedCentralGoogle Scholar
- Haddow LJ, Laverick R, Daskalopoulou M, McDonnell J, Lampe FC, Gilson R, Speakman A, Antinori A, Balestra P, Bruun T, Gerstoft J, Nielsen L, Vassilenko A, Collins S, Rodger AJ (2018) Multicenter European prevalence study of neurocognitive impairment and associated factors in HIV positive patients. AIDS Behav 22(5):1573–1583CrossRefPubMedCentralGoogle Scholar
- Harrington PR, Schnell G, Letendre SL, Ritola K, Robertson K, Hall C, Burch CL, Jabara CB, Moore DT, Ellis RJ, Price RW, Swanstrom R (2009) Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. Aids 23:907–915CrossRefPubMedPubMedCentralGoogle Scholar
- Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 75:2087–2096CrossRefPubMedPubMedCentralGoogle Scholar
- Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, Group C, Group H (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neuro-Oncol 17:3–16Google Scholar
- Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K, Team ACTGS (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23:1359–1366CrossRefPubMedPubMedCentralGoogle Scholar
- McGuire JL, Gill AJ, Douglas SD, Kolson DL (2015) Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders. J Neuro-Oncol 21:439–448Google Scholar
- Milanini B, Ciccarelli N, Fabbiani M, Baldonero E, Limiti S, Gagliardini R, Borghetti A, D'Avino A, Mondi A, Colafigli M, Cauda R, Di Giambenedetto S (2016) Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal cognitive assessment (MoCA) and mini mental state examination (MMSE). Clin Neuropsychol 30:1457–1468CrossRefPubMedGoogle Scholar
- Peluso MJ, Meyerhoff DJ, Price RW, Peterson J, Lee E, Young AC, Walter R, Fuchs D, Brew BJ, Cinque P, Robertson K, Hagberg L, Zetterberg H, Gisslen M, Spudich S (2013) Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis 207:1703–1712CrossRefPubMedPubMedCentralGoogle Scholar
- Rahimy E, Li FY, Hagberg L, Fuchs D, Robertson K, Meyerhoff DJ, Zetterberg H, Price RW, Gisslen M, Spudich S (2017) Blood-brain barrier disruption is initiated during primary HIV infection and not rapidly altered by antiretroviral therapy. J Infect Dis 215:1132–1140CrossRefPubMedPubMedCentralGoogle Scholar
- Ryan LA, Zheng J, Brester M, Bohac D, Hahn F, Anderson J, Ratanasuwan W, Gendelman HE, Swindells S (2001) Plasma levels of soluble CD14 and tumor necrosis factor-alpha type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection. J Infect Dis 184:699–706CrossRefPubMedGoogle Scholar
- Sevigny JJ, Albert SM, McDermott MP, McArthur JC, Sacktor N, Conant K, Schifitto G, Selnes OA, Stern Y, McClernon DR, Palumbo D, Kieburtz K, Riggs G, Cohen B, Epstein LG, Marder K (2004) Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 63:2084–2090CrossRefPubMedGoogle Scholar
- Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B, Fuchs D, Tambussi G, Cinque P, Hecht FM, Price RW (2011) Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis 204:753–760CrossRefPubMedPubMedCentralGoogle Scholar
- Trunfio M, Vai D, Montrucchio C, Alcantarini C, Livelli A, Tettoni MC, Orofino G, Audagnotto S, Imperiale D, Bonora S, Di Perri G, Calcagno A (2018) Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders. HIV Med. https://doi.org/10.1111/hiv.12622 CrossRefGoogle Scholar
- Valcour V, Chalermchai T, Sailasuta N, Marovich M, Lerdlum S, Suttichom D, Suwanwela NC, Jagodzinski L, Michael N, Spudich S, van Griensven F, de Souza M, Kim J, Ananworanich J (2012) Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 206:275–282CrossRefPubMedPubMedCentralGoogle Scholar
- Vandergeeten C, Fromentin R, Merlini E, Lawani MB, DaFonseca S, Bakeman W, McNulty A, Ramgopal M, Michael N, Kim JH, Ananworanich J, Chomont N (2014) Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. J Virol 88:12385–12396CrossRefPubMedPubMedCentralGoogle Scholar
- Vassallo M, Durant J, Lebrun-Frenay C, Fabre R, Ticchioni M, Andersen S, DeSalvador F, Harvey-Langton A, Dunais B, Cohen-Codar I, Montagne N, Cua E, Fredouille-Heripret L, Laffon M, Cottalorda J, Dellamonica P, Pradier C (2015) Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation. HIV Med 16:431–440CrossRefPubMedGoogle Scholar
- Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, Drummond F, Vjecha MJ, Hoy J, Miller C, Penalva de Oliveira AC, Pumpradit W, Shlay JC, El-Sadr W, Price RW (2010) Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 75:864–873CrossRefPubMedPubMedCentralGoogle Scholar
- Yilmaz A, Blennow K, Hagberg L, Nilsson S, Price RW, Schouten J, Spudich S, Underwood J, Zetterberg H, Gisslen M (2017) Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev Mol Diagn 17(8):761–770CrossRefPubMedGoogle Scholar